Want to see HK:1877 full AI Analyst Report?
Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$14.50
▼(-47.35% Downside)
Action:Reiterated
Date:10/31/26
The score is mainly constrained by weak cash flow and rising leverage despite strong revenue growth and high gross margins, indicating continued funding risk. Technicals add further pressure due to a clear downtrend and negative momentum, while valuation support is limited because the company remains loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Revenue Growth and Gross Margin
TTM revenue growth of 598% alongside gross margins near 79–81% indicates strong commercial traction and substantial product-level economics. If maintained, this combination gives Junshi room to fund development, expand indications, and convert scale into improving earnings over coming quarters.
Negative Factors
Continued Operating Losses
Junshi has not yet achieved sustained operating profitability, with EBIT, EBITDA, and net income still negative. This limits internally generated funding, leaves results sensitive to development and commercialization spending, and means growth must continue before earnings become self-supporting.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
TTM revenue growth of 598% alongside gross margins near 79–81% indicates strong commercial traction and substantial product-level economics. If maintained, this combination gives Junshi room to fund development, expand indications, and convert scale into improving earnings over coming quarters.
Read all positive factors
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.07B
Dividend YieldN/A
Average Volume (3M)1.69M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth35.82%
EPS Growth54.40%
CountryHK
Employees2,903
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding260,295,700
10 Day Avg. Volume1,433,690
30 Day Avg. Volume1,688,097
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.65Price Target Upside-6.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)HK$3.36B
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic...
How the Company Makes Money
Junshi Biosciences primarily makes money through (1) product sales from commercialized drugs and (2) collaboration-related income tied to partnering its drug assets.
1) Product sales (core operating revenue)
- The company generates revenue by sel...
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
50
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.18B | 2.43B | 1.95B | 1.50B | 1.45B | 4.02B |
| Gross Profit | 2.54B | 1.97B | 1.54B | 835.26M | 927.21M | 2.77B |
| EBITDA | -211.43M | -599.38M | -882.37M | -2.16B | -2.47B | -423.50M |
| Net Income | -423.75M | -851.76M | -1.28B | -2.28B | -2.39B | -718.56M |
Balance Sheet | ||||||
| Total Assets | 14.92B | 12.39B | 10.80B | 11.36B | 12.58B | 11.05B |
| Cash, Cash Equivalents and Short-Term Investments | 4.37B | 3.22B | 2.93B | 3.78B | 6.00B | 3.50B |
| Total Debt | 6.82B | 4.14B | 2.93B | 1.79B | 1.32B | 628.20M |
| Total Liabilities | 8.89B | 6.16B | 4.85B | 4.02B | 2.78B | 2.72B |
| Stockholders Equity | 5.83B | 6.03B | 5.86B | 7.17B | 9.50B | 7.96B |
Cash Flow | ||||||
| Free Cash Flow | -750.95M | -1.21B | -2.12B | -2.85B | -2.17B | -1.53B |
| Operating Cash Flow | 40.32M | -465.77M | -1.43B | -2.01B | -1.78B | -641.90M |
| Investing Cash Flow | -2.46B | -1.58B | -892.78M | -892.42M | -467.62M | -1.88B |
| Financing Cash Flow | 3.18B | 2.17B | 1.02B | 681.04M | 4.64B | 2.67B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Negative
27.54
Price Trends
17.63
Negative
17.92
Negative
20.34
Negative
Market Momentum
-0.60
Positive
35.45
Neutral
14.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1877, the sentiment is Negative. The current price of 27.54 is above the 20-day moving average (MA) of 16.84, above the 50-day MA of 17.63, and above the 200-day MA of 20.34, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 35.45 is Neutral, neither overbought nor oversold. The STOCH value of 14.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1877.
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$51.82B | 7.90 | 105.60% | ― | 292.84% | ― | |
63 Neutral | HK$139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
52 Neutral | HK$21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:1801
Innovent Biologics
79.75
-10.45
-11.59%
HK:9688
Zai Lab Ltd
17.37
-3.65
-17.36%
HK:9926
Akeso, Inc.
81.50
-36.80
-31.11%
HK:9995
RemeGen Co. Ltd. Class H
64.85
-28.00
-30.16%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Junshi Biosciences Tightens Cash Management of Idle Fundraising Proceeds
Oct 29, 2026
Shanghai Junshi Biosciences has approved a new plan to manage a portion of its temporarily idle fundraising proceeds through principal‑guaranteed, highly liquid investment products. The 12‑month authorization, effective from 27 Novembe...
Junshi Biosciences Publishes PRC-Standard Q3 2026 Financials for Cross-Market Investors
Oct 29, 2026
Shanghai Junshi Biosciences has released its unaudited 2026 third quarterly report on the Shanghai Stock Exchange’s STAR Market, prepared under PRC accounting principles rather than International Financial Reporting Standards. The announceme...
Junshi Biosciences Plans Online Briefing on Q3 2026 Results
Oct 29, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced that it will hold an online briefing on its third-quarter 2026 financial results via the Shanghai Stock Exchange Roadshow Center. The session, scheduled for 5 November 2026, is designed to give i...
Junshi Biosciences Starts Phase III Trial of JS207–JS007 Combo for Advanced Liver Cancer
Oct 29, 2026
Shanghai Junshi Biosciences has completed first patient dosing in a phase III, multi-center clinical trial evaluating its bispecific antibody JS207 combined with CTLA-4 inhibitor JS007 as a first-line treatment for advanced hepatocellular carcinom...
Junshi Wins Full China Approval for Toripalimab in Advanced Urothelial Cancer
Oct 28, 2026
Shanghai Junshi Biosciences announced that China’s National Medical Products Administration has converted the indication for toripalimab injection as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who hav...
Junshi Biosciences’ Subcutaneous Toripalimab Application Accepted for HER2-Positive Urothelial Cancer
Oct 28, 2026
Shanghai Junshi Biosciences has received acceptance from China’s National Medical Products Administration for a supplemental new drug application covering toripalimab subcutaneous injection, JS001sc, in combination with disitamab vedotin for...
Junshi Biosciences Starts Phase III Trial of Bispecific Antibody JS203 in Aggressive Lymphoma
Oct 23, 2026
Shanghai Junshi Biosciences has completed first patient dosing in a randomized, open-label, multicenter phase III trial of its bispecific antibody JS203 combined with chemotherapy in relapsed or refractory diffuse large B-cell lymphoma, comparing ...
Junshi Biosciences Sets Board Meeting to Approve Nine-Month Unaudited Results
Oct 15, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for October 29, 2026 to review and approve the group’s unaudited financial results for the nine months ended September 30, 2026. The announcement underscores the companyR...
Junshi Biosciences Grants Reserved A Share Options Under 2025 Incentive Scheme
Sep 23, 2026
Shanghai Junshi Biosciences has approved a reserved grant of 715,000 A share options to 16 participants under its 2025 A Share Option Incentive Scheme, equivalent to about 0.07% of its total share capital. The options, priced at RMB46.67 per share...
Shanghai Junshi Biosciences Board Confirms Option Plan Milestone and Cancels Some Options
Sep 23, 2026
Shanghai Junshi Biosciences has announced the outcomes of the twenty-third meeting of the fourth session of its board of directors, held on 23 September 2026 through a combination of on-site participation and correspondence voting. All 14 director...
Shanghai Junshi Biosciences Sets Date for 2026 Interim Results Investor Briefing
Sep 4, 2026
Shanghai Junshi Biosciences has announced that it will hold its 2026 interim results briefing on 14 September 2026 via the Shanghai Stock Exchange Roadshow Center, using an online interactive format.The session aims to give investors a deeper unde...
Junshi Biosciences Discloses Planned Stake Reduction by Key A-Share Investor
Aug 31, 2026
Shanghai Junshi Biosciences announced an overseas regulatory disclosure relating to a shareholder’s plan to reduce its stake in the company. The notice, issued under Hong Kong listing rules, underscores the firm’s adherence to cross-ma...
Junshi Biosciences Board Approves 2026 Interim Report at Fully Attended Meeting
Aug 26, 2026
Shanghai Junshi Biosciences announced that its board of directors held the twenty-second meeting of the fourth session on 26 August 2026, with all 14 directors attending either on-site or via correspondence. The company confirmed that the meeting ...
Shanghai Junshi Biosciences Ends 2026 Employee Stock Ownership Scheme
Aug 26, 2026
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong. The company develops and commercializes innovative medicines, with a focus on sustaining long-term growth t...
Shanghai Junshi Biosciences Boosts Revenue, Returns to Profit on TUOYI Growth and Strong Financing
Aug 26, 2026
Shanghai Junshi Biosciences reported interim results for the six months ended 30 June 2026 showing strong top-line growth driven by its core immuno-oncology drug TUOYI and higher out-licensing revenue. The company maintained substantial investment...
Shanghai Junshi Biosciences Completes RMB0.7 Billion Technology Innovation Bond Issuance
Aug 21, 2026
Shanghai Junshi Biosciences has completed the issuance of its 2026 third tranche of technology innovation bonds, raising RMB0.7 billion in three-year notes at an interest rate of 2.55%. The funds were received on 21 August 2026, with the bonds set...
Junshi Biosciences Details Stake Reduction by Key Pre-IPO Shareholder
Aug 19, 2026
Shanghai Junshi Biosciences announced the completion of a shareholding reduction by substantial shareholder Shanghai Tanying Investment Partnership, which previously held 59,459,326 A shares, or 5.79% of the company’s total share capital. Th...
Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results
Aug 12, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for 26 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026. The session may also address other corporate matters, u...
Junshi Biosciences Discloses Reduction in Major Shareholder’s Equity Stake
Aug 10, 2026
Shanghai Junshi Biosciences reported a change in equity holdings by major shareholder Shanghai Tanying Investment Partnership and its concerted parties, Loyal Valley Capital Advantage Fund II and LVC Renaissance Fund. Their combined stake in the c...
Shanghai Junshi Biosciences Reports Completion of Shareholder’s Stake Reduction
Aug 10, 2026
Shanghai Junshi Biosciences has disclosed the outcome of a shareholding reduction by substantial shareholder He Ming, who previously held 3,531,380 A shares, representing 0.3440% of the company’s total share capital. These shares were largel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.